[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.48.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
January 28, 1956

FURTHER EVALUATION OF ACETAZOLAMIDE (DIAMOX) IN TREATMENT OF EPILEPSY

Author Affiliations

Boston

From the Seizure Unit, Children's Medical Center, and the Department of Pediatrics, Harvard Medical School.

JAMA. 1956;160(4):268-272. doi:10.1001/jama.1956.02960390018006
Abstract

• Acetazolamide, by inhibiting the carbonic anhydrase throughout the body, causes profound metabolic changes and affects the acid-base balance of blood and body fluids. Administered by mouth in a series of 126 patients with various forms of epilepsy, it gave practically complete control of seizures in 34 cases and a 90 to 99% reduction of seizures in an additional 12 cases. In no case was the condition made worse. No serious abnormalities of blood, urine, or bone were observed during treatment, which was maintained over periods from three months to three years.

The beneficial effects were not clearly correlated with either the dosage of the drug or the level of carbonic anhydrase activity in the blood. These facts suggest that the drug may act rather directly on the metabolism of cerebral neurones.

×